ArticleScientific reports2018
Donor-derived cell-free DNA is associated with acute rejection and decreased oxygenation in primary graft dysfunction after living donor-lobar lung transplantation.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation.Frontiers in immunology · 2023Pooled it
- Human biomarker navigator.iMeta · 2026Review
- Exploring donor-derived cell-free DNA as a rejection biomarker during uterus transplant follow up.Communications medicine · 2026Article
- Early post-transplant recipient tissue injury predicts allograft function, rejection and survival in lung transplant recipients: evidence from cell-free DNA.The European respiratory journal · 2026Article
- Correlation between acute cellular rejection detected with cryobiopsy and elevated donor-derived cell-free DNA in lung transplant recipients.JHLT open · 2026Article
- Correlation between acute cellular rejection detected with cryobiopsy and elevated dd-cfDNA in lung transplant recipients.JHLT open · 2026Article
- The Effect of Aligned and Random Electrospun Fibers Derived from Porcine Decellularized ECM on Mesenchymal Stem Cell-Based Treatments for Spinal Cord Injury.Bioengineering (Basel, Switzerland) · 2024Article
- Application of graft-derived cell-free DNA for solid organ transplantation.Frontiers in immunology · 2024Review
- Molecular monitoring of lung allograft health: is it ready for routine clinical use?European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Application of plasma donor-derived cell free DNA for lung allograft rejection diagnosis in lung transplant recipients.BMC pulmonary medicine · 2023Article
- Clinical relevance of cell-free DNA quantification and qualification during the first month after lung transplantation.Frontiers in immunology · 2023Article
- Single center study investigating the clinical association of donor-derived cell-free DNA with acute outcomes in lung transplantation.Frontiers in transplantation · 2023Article
- Jinlian Xiaodu Decoction Protects against Bleomycin-Induced Pulmonary Fibrosis in Rats.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Validation of a Simple, Rapid, and Cost-Effective Method for Acute Rejection Monitoring in Lung Transplant Recipients.Transplant international : official journal of the European Society for Organ Transplantation · 2022Article
- The prognostic nutritional index is correlated negatively with the lung allocation score and predicts survival after both cadaveric and living-donor lobar lung transplantation.Surgery today · 2021Article
- Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2021Article
- Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD).The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2021Observational
- Donor-derived Cell-free DNA: Advancing a Novel Assay to New Heights in Renal Transplantation.Transplantation direct · 2021Article
- Usefulness of a preoperative inflammatory marker as a predictor of asymptomatic acute rejection after lung transplantation: a Japanese single-institution study.Journal of thoracic disease · 2020Article
- Lung perfusion scintigraphy to detect chronic lung allograft dysfunction after living-donor lobar lung transplantation.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Donor-derived cell-free DNA (dd-cf-DNA) has been shown to be an informative biomarker of rejection after lung transplantation (LT) from deceased donors. However, in living-donor lobar LT, because small grafts from blood relatives are implanted with short ischemic times, the detection of dd-cf-DNA might be challenging. Our study was aimed at examining the role of dd-cf-DNA measurement in the diagnosis of primary graft dysfunction and acute rejection early after living-donor lobar LT. Immediately after LT, marked increase of the plasma dd-cf-DNA levels was noted, with the levels subsequently reaching a plateau with the resolution of primary graft dysfunction. Increased plasma levels of dd-cf-DNA were significantly correlated with decreased oxygenation immediately (p = 0.022) and at 72 hours (p = 0.046) after LT. Significantly higher plasma dd-cf-DNA levels were observed in patients with acute rejection (median, 12.0%) than in those with infection (median, 4.2%) (p = 0.028) or in a stable condition (median, 1.1%) (p = 0.001). Thus, measurement of the plasma levels of dd-cf-DNA might be useful to monitor the severity of primary graft dysfunction, and plasma dd-cf-DNA could be a potential biomarker for the diagnosis of acute rejection after LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.